Sponsored by: Celvivo
Chaired by: Stefan Przyborski, Professor of Cell Technology, Durham University

Developing Complex Physiologically Relevant Cell Models in Vitro

3D Cell Culture is gaining momentum in the pharmaceutical industry, with the global 3D Cell Culture market predicted to surpass a value of $ Billion by 2027. Researchers globally are realising the potential of in vitro applications for drug discovery, predictivity and validation, safety, and toxicity.

SMi’s 5th Annual 3D Cell Culture Conference will be covering the application of 3D cell culture to drug development, toxicity testing, and safety assurance. In addition, the conference will look into the newest breakthroughs in Organ Chip technology, 3D Multicellular scaffolding, Microphysiological Systems, and 3D Bioprinting. In recent years technological advances have made these technologies viable and accessible in scientific application.

Event Hashtag: #SMi3DCellCulture

HIGHLIGHTS FOR 2021

• Discover the cutting-edge technology that is changing the face of pharmaceutical drug development
• Explore the necessity of utilising 3D models in the cytotoxic testing of biologics over traditional alternatives
• Insight into the capacity for microphysiological systems and organ-on-a-chip technology to mimic cellular microenvironments in vitro
• Discuss current case studies in applied 3D cell models that are changing the future of pharmaceutical drug discovery
• Assess the biophysiological competency of MPS and 3D Bioprinting at the pre-conference workshops

FEATURED SPEAKERS INCLUDE:

• Suzanne Fitzpatrick, Senior Advisor for Toxicology, US Food and Drug Administration
• Pelin Candarlioglu, Investigator - Bioengineer/Cell Biologist, GSK
• Robert Vries, CEO, Hubrecht organoid Technology
• Sakshi Garg, Lab Head, Discovery & Development Technologies, Merck Group
• Rhiannon David, Scientific Lead Microphysiological Systems, AstraZeneca
• Stephen J. fey, Founder and Chief Research Officer, CelVivo
• Alejandro Amador, Director, Cellular Assays and Technologies, Incyte
• Freddy Van Goethem, Scientific Director - Fellow, Predictive, Investigative, and Translational Toxicology, Johnson & Johnson; Janssen Pharmaceutical
• Julian Bahr, Postdoctoral Fellow, Oncology, AstraZeneca
• Pedro Pinto, Laboratory Manager, Urology, university of Greifswald – Medical Centre

WHO SHOULD ATTEND?

Biotech / Pharma Companies - Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist

Academia Professor - Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering

Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO

Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer